CAMBREX : WINS API DEVELOPMENT AWARD AT CPhI WORLDWIDE FOR SECOND CONSECUTIVE YEAR

East Rutherford, NJ - 9 November, 2017 - Cambrex Corporation (NYSE: CBM) the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has won the 'API Development' category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Frankfurt on October 24th. This marks the second successive year that Cambrex has been successful in this category.

The winning entry presented a case study which examined an alternative route developed by Cambrex towards the drug ospemifene, used for the treatment of dyspareunia.

The original published synthetic route was a seven-step process which involved multiple purification and recrystallization steps. Cambrex developed a robust, commercially scalable process using standard plant equipment, and needing only two synthetic steps and one recrystallization. Waste was minimized, and the use of solvents dramatically reduced with recycling and reuse where possible.

The resulting, final API is of an extremely high purity, and this, along with a three-fold increase in yield offers a considerable reduction of the cost of goods.

'We are very pleased to have won this prestigious award in two consecutive years, having been recognized for our approach to the synthesis of dronedarone in 2016,' commented Jonathan Knight, Vice President, New Product Development at Cambrex. He added, 'We thank our industry peers and editors on the judging panel for acknowledging the innovative approach that Cambrex's technical team applied in this novel route for the production of ospemifene.'

Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. The awards celebrate thinkers and creators breaking new ground and strongly advocate companies committed to driving the industry forward.

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com

Cambrex Corporation